AVITA Medical to Host Investor Webinar Briefing

Rhea-AI Summary

AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on November 12, 2025 at 2:00 p.m. PT (November 13, 2025 at 9:00 a.m. AEDT).

Interim CEO Cary Vance and CFO David O’Toole will review financial and business results from the company’s recent Q3 2025 earnings webcast and hold a live Q&A. Shareholders and prospective investors may register to submit questions in advance. A replay will be available on AVITA Medical’s investor website after the presentation.

VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on November 12, 2025, at 2:00 p.m. U.S. Pacific Standard Time (November 13, 2025, at 9:00 a.m. Australian Eastern Daylight Time).

The webinar presentation will cover financial and business results from AVITA Medical’s recent third-quarter 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.

Register: https://us06web.zoom.us/webinar/register/WN_1hW79Y7fR5y2tIVc1zdePQ

A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.

About AVITA Medical, Inc.

AVITA Medical^® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL^® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm^®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

FAQ

When is the AVITA Medical (RCEL) investor webinar briefing?

The webinar is scheduled for November 12, 2025 at 2:00 p.m. Pacific Time (November 13, 2025 at 9:00 a.m. AEDT).

Who will present at the AVITA Medical (RCEL) investor webinar on November 12, 2025?

Presenters are Interim CEO Cary Vance and CFO David O’Toole.

What will AVITA Medical (RCEL) cover in the November 12, 2025 webinar?

The presentation will review financial and business results from Q3 2025 and include a live Q&A.

How can investors register for the AVITA Medical (RCEL) webinar?

Investors can register via the webinar registration page provided by the company prior to the event.

Will a replay of the AVITA Medical (RCEL) November 12, 2025 webinar be available?

Yes. A replay will be posted on AVITA Medical’s investor website following the presentation.

Can shareholders submit questions ahead of the AVITA Medical (RCEL) webinar?

Yes. Participants are invited to submit questions via the registration page before the webinar.